Evaluation of Efficacy and Patient Satisfaction of Local Anaesthesia Versus Sedoanalgesia for Botox (R) Injection in the Urinary Bladder for the Treatment of Idiopathic Overactive Bladder
- Sponsor
- Hospital LKH Hochsteiermark - Leoben
- Study ID
- NCT06437899
- Status
- Enrolling By Invitation
Conditions
- Overactive Bladder
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- intravesical botulinum toxin A injection unter local anaesthesia — DRUGArm1: Botulinum toxin A injection under local anesthesia according to standard protocol: Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol: Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor.
Study Details
Patients with symptoms of overactive bladder suffer from frequent micturition, urinary incontinence and recurrent urinary tract infections. Intravesical injections with botulinum toxin A can be used as a second-line therapy for this purpose. Intravesical botulinum toxin A injections can be performed under general anesthesia, regional anesthesia, sedoanalgesia and local anesthesia. Which form of anesthesia is used varies greatly from region to region. As these patients are often elderly and morbid, the lowest-risk and least stressful anesthesia method should be used. The lowest-risk anesthesia method that can be used is local anesthesia. Currently, there are no guidelines that describe the use of standardized protocols for local anesthesia. The aim of this study is to show that the use of local anesthesia in this context is not inferior to the use of sedoanalgesia. All patients with overactive bladder symptoms who fulfill the inclusion criteria and present at the Urogynecology Outpatient Clinic of the Department of Gynecology and Obstetrics at the LKH Hochsteiermark in Leoben within 24 months will be invited to participate in the study. The main outcome measure is pain, secondary outcome measures are quality of life, patient satisfaction, incontinence score, operation time and length of stay in the recovery room, acceptance of repeating the procedure under local anesthesia, satisfaction with the type of anesthesia method, side effects/complications and duration of inpatient stay. The study will be randomized into 2 arms (local anesthesia/sedoanalgesia) with a 1:1 ratio to carry out the intravesical injection with botulinum toxin A.
Key Dates
- First listed
- May 31, 2024
- Start date
- Sep 1, 2023
- Status verified
- May 2024
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 84 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: local anaesthesia
- Active Comparator: sedoanalagesia
Primary Outcome Measure
pain assessed by numeric rating scale [ Time Frame: twentyfour hours ]
Related Studies
- Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive BladderPHASE4 · Recruiting · Walter Reed National Military Medical Center · Bethesda, Maryland
- Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead PlacementRecruiting · Loma Linda University · Loma Linda, California
- Antibiotic Usage Prior to OnabotulinumtoxinA InjectionRecruiting · Benaroya Research Institute · Stony Brook, New York
- BTL Emsella Chair Versus Sham for the Treatment of Overactive BladderRecruiting · Corewell Health East · Royal Oak, Michigan